# Antiverse

> Antiverse is a UK-based AI-driven biotech that designs functional therapeutic antibodies against targets long considered 'undruggable' - notably G-protein coupled receptors (GPCRs), ion channels, and other transmembrane proteins where conventional antibody discovery routinely fails. Its platform pairs generative AI models, trained for years on the hardest antibody targets, with a proprietary 'lab-in-the-loop' wet lab using engineered cell lines and deep sequencing, taking a target to an optimized antibody in roughly four months. Founded in 2017 and headquartered in Cardiff, Wales, the company works through pharma partnerships and licensing (e.g. Nxera Pharma) alongside its own internal pipeline and non-profit collaborations such as the Cystic Fibrosis Foundation.

- **Founded:** 2017
- **Headquarters:** Cardiff, Wales, United Kingdom
- **Founders:** Murat Tunaboylu (Co-Founder & CEO), Ben Holland (Co-Founder & CTO), Rowina Westermeier (Co-Founder (departed ~2019))
- **Team size:** ~38 employees (2026)
- **Products:** Generative AI antibody design platform, Lab-in-the-loop wet lab & engineered cell lines, Deep sequencing & multiparameter clustering, Partnered & internal therapeutic pipeline
- **Notable:** Founded in 2017 out of Deep Science Ventures in London., Signed a multi-target GPCR antibody collaboration and licensing deal with Nxera Pharma (Nov 2024)., Raised a $9.3M Series A in March 2026, bringing cumulative funding to roughly $20M+.

## Products & services

- **Generative AI antibody design platform** — Proprietary generative/machine-learning models that design target-specific antibody sequences de novo from a target sequence or structure, using epitope-specific libraries trained for years on hard transmembrane targets.
- **Lab-in-the-loop wet lab & engineered cell lines** — Proprietary cell lines that hyper-express millions of receptor copies, enabling rapid experimental screening of AI-designed antibody libraries against real biological targets and feedback into the models.
- **Deep sequencing & multiparameter clustering** — Selection and optimization of antibody leads across ~20 developability and functional properties to identify optimized candidates.
- **Partnered & internal therapeutic pipeline** — Around nine active discovery programmes spanning oncology, cardiovascular (PAR1 GPCR), CNS, idiopathic pulmonary fibrosis and cardiometabolic targets, including partnered oncology candidates in preclinical development.

## Achievements

- Founded in 2017 out of Deep Science Ventures in London.
- Signed a multi-target GPCR antibody collaboration and licensing deal with Nxera Pharma (Nov 2024).
- Raised a $9.3M Series A in March 2026, bringing cumulative funding to roughly $20M+.
- Entered a research agreement with the Cystic Fibrosis Foundation to design antibodies against CFTR (2026).
- Reports designing target-to-optimized antibodies in about four months, with high blinded-study accuracy against difficult targets.
- Built ~9 active discovery programmes across oncology, cardiovascular, CNS, fibrosis and cardiometabolic disease.

## Latest updates

- **2026-03** — Raised a $9.3M Series A led by Soulmates Ventures and announced a research agreement with the Cystic Fibrosis Foundation to design antibodies against CFTR.
- **2024-11** — Entered a multi-target GPCR antibody collaboration and licensing agreement with Nxera Pharma.
- **2024-10** — Closed a £3.5M seed extension led by i&i Biotech Fund and Kadmos Capital to advance its generative AI antibody design platform.

## Links

- Website: https://antiverse.io
- LinkedIn: https://www.linkedin.com/company/antiverse
- Twitter/X: https://x.com/AntiverseHQ
- YouTube: https://www.youtube.com/@AntiverseHQ

---

Profile page: https://yespress.io/antiverse
Published by YesPress — https://yespress.io
Last updated: 2026-07-22